Look for keystone conference - this link is a pain in the ass so you have to search through and you will get eventually page with text below. I believe that the ED gene therapy presentation is either a poster or late accepted talk hence you will not find it on this programme.
colorado.net
******
Return to 1999 Keystone Symposia
Molecular and Cellular Biology of Gene Therapy (A4)
Doubletree Hotel, Salt Lake City, Utah · January 14 - January 20, 1999
Organizers: Bonnie W. Ramsey, Mark Kay, Malcolm Brenner and Alan Smith
Sponsored by Berlex Biosciences
Abstract Deadline: September 15, 1998 · Early Registration: November 13, 1998
Summary
The goal of this conference is to highlight progress in both molecular and cellular biology,
clinical studies to establish a basic framework for clinical trial development in human gene
therapy. The results of recent clinical trails will be presented. Major barriers to human studies,
including limitation of current vectors, host immune response, stem cell biology and disease
pathogenesis will be discussed. The meeting will bring together basic scientists and clinical
investigators to face these challenges. The program will focus on innovative technologies in
vector development (novel vectors, combination chemistry, anti-sense ribozyme technology),
vector-host interactions, challenges of clinical trial development, genetic diseases, stem cell
biology, vascular diseases, CNS disorders, AIDS, cancer, and vaccine development. Each
session will highlight the basic science, preclinical studies and review current clinical trials.
Thursday, January 14
2:00 pm-7:00 pm
Registration
6:30 pm-7:30 pm
Welcome
7:30 pm-8:00 pm
Orientation
8:00 pm-9:00 pm
Keynote Address
KEYNOTE SPEAKER
Malcolm K. Brenner, Baylor College of Medicine
Success and Challenges of Clinical Trials in Gene Therapy
Friday, January 15
7:00 am-8:00 am
Breakfast
8:00 am-11:00 am
Plenary Session
INNOVATIVE TECHNOLOGIES
* C. Thomas Caskey, Merck Research Laboratories
Helper Dependent Ad Vection - Improved Safety, Longevity of Expression, and Production
Clifford J. Steer, University of Minnesota
Correction of Genetic Diseases in Liver Resulting from Single Nucleotide Mutations in
Genomic DNA
Perry B. Hackett, University of Minnesota
Activity of the Sleeping Beauty System in Mammalian Cells
Willem P.C. Stemmer, Maxygen, Inc.
Directed Evolution of Proteins, Pathways, Episomes and Viruses by DNA Shuffling
Garry P. Nolan, Stanford University
De novo Evolution of Peptidic Modules for Therapeutic Manipulation of Cellular Physiology
11:00 am-1:00 pm
Poster Setup
4:30 pm-6:30 pm
Poster Session 1
Innovative Technologies and Vector Development (I)
5:30 pm-6:30 pm
Social Hour
8:00 pm-10:00 pm
Plenary Session
HOST, VECTOR, TRANSGENE INTERACTIONS
Thomas J. Wickham, GenVec, Inc.
Adenovirus Vector Targeting
Richard J. Gregory, Genzyme Corporation
Circumventing Barriers to Gene Transfer
* Michael J. Welsh, University of Iowa
New Approaches for Gene Transfer to Airway Epithelia
Saturday, January 16
7:00 am-8:00 am
Breakfast
8:00 am-11:00 am
Plenary Session
INNOVATIVE TECHNOLOGIES
* Alan E. Smith, Genzyme Corporation
Carl O. Pabo, Massachusetts Institute of Technology
Design of C2H2 Zinc Finger Proteins for Potential Applications in Gene Therapy
Hermann G. Bujard, University of Heidelberg
Controlling Genes via Tetracycline: Does the System Hold Promise for Gene Therapy?
Inder M. Verma, Salk Institute
Lentiviral Vectors
11:00 am-1:00 pm
Poster Setup
4:30 pm-6:30 pm
Poster Session 2
Innovative Technologies (II) and Host-Vector Interactions
5:30 pm-6:30 pm
Social Hour
8:00 pm-10:00 pm
Plenary Session
GENETIC DISORDERS I
* Donald B. Kohn, Children's Hospital Los Angeles
Lentiviral Vectors Show Improved Gene Transfer in Human Hematopoietic Stem Cells
Jeffrey S. Chamberlain, University of Michigan
A Gutted Adenoviral Vector System for Gene Therapy of Muscular Dystrophy
Sunday, January 17
7:00 am-8:00 am
Breakfast
8:00 am-11:00 am
Plenary Session
GENETIC DISORDERS II
Katherine A. High, Children's Hospital
Long-term Correction of Hemophilia B by Muscle-derived Expression of Coagulation Factor IX
Michael Kaleko, Genetic Therapy Inc
Gene Therapy for Hemophilia A
James M. Wilson, University of Pennsylvania
DNA Viral-Vectors for Genetic Diseases
* Bonnie W. Ramsey, University of Washington
Clinical Trials in Cystic Fibrosis - Is the Cup Half Full or Half Empty?
11:00 am-1:00 pm
Poster Setup
4:30 pm-6:30 pm
Poster Session 3
Genetic Disorders/Stem Cell Biology
5:30 pm-6:30 pm
Social Hour
8:00 pm-10:00 pm
Plenary Session
LATE BREAKING SCIENCE: PRESENTATIONS TO BE SELECTED FROM ABSTRACTS
* Mark A. Kay, Stanford University
Monday, January 18
7:00 am-8:00 am
Breakfast
8:00 am-11:00 am
Plenary Session
CANCER
* Malcolm K. Brenner, Baylor College of Medicine
Savio L.C. Woo, Mount Sinai School of Medicine
Active Genetic Immunization Against Metastatic Colon Carcinoma by Gene Therapy in vivo
Gary J. Nabel, University of Michigan
Gene Transfer Approaches to Immune Activation and Suppression in Malignancy
David H. Kirn, Onyx Pharmaceuticals
Clinical Trials with a Selectively-Replicating Adenovirus, ONYX-015
Brian Sorrentino, St. Jude Children's Hospital
In vivo Selection of Hematopoietic Stem Cells Using DHFR-expressing Vectors
11:00 am-1:00 pm
Poster Setup
4:30 pm-6:30 pm
Poster Session 4
Cancer/Cardiovascular Disorders/Other Applications
5:30 pm-6:30 pm
Social Hour
8:00 pm-10:00 pm
Plenary Session
CARDIOVASCULAR DISORDERS
* Elizabeth G. Nabel, University of Michigan
Regulation of Smooth Muscle Cell Growth by Cell Cycle Regulatory Proteins
Helen M. Blau, Stanford University
Dose-dependent Effects of VEGF Delivery on the Development of Vascular Structures
Victor J. Dzau, Brigham and Women's Hospital
Anti-Inflammatory Therapy: Nitric Oxide Pathway
Jeffrey M. Isner, St. Elizabeth Medical Center
Myocardial Angiogenesis
Tuesday, January 19
7:00 am-8:00 am
Breakfast
8:00 am-11:00 am
Plenary Session
STEM CELL BIOLOGY
* John E. Dick, Hospital For Sick Children
What have in vivo Assays Taught us About Human Hematopoietic Stem Cells?
Terence A. Partridge, Imperial College
The Nature of Myogenic Stem Cells Involved in Muscle Growth and Regeneration
Fred H. Gage, Salk Institute
Self-Renewing Multipotent Cells in the Adult Brain
Markus Grompe, Oregon Health Sciences University
Liver Stem Cells and Therapeutic Liver Repopulation
3:00 pm-5:00 pm
Plenary Session
OTHER CLINICAL APPLICATIONS OF GENE THERAPY
Flossie Wong-Staal, University of California-San Diego
Lentiviral Vectors for Antiviral and Immune-based Therapies
* Mark A. Kay, Stanford University
Hepatic Gene Therapy for Hemophilia and Other Liver Diseases
Si-Yi Chen, Baylor College of Medicine
Intrakine Targeting Chemokine Receptors for HIV-1 H Gene Therapy
7:00 pm-8:00 pm
Social Hour
8:00 pm-10:00 pm
Banquet
9:00 pm-12:00 pm
Entertainment
Wednesday, January 20
Departure
* Chair
† Invited, not yet responded
Copyright © 1999 Keystone Symposia
Last Updated: 11/30/98 keystone@symposia.com
|
